Sugi Predict

Sugi Predict / Compounds / SCHEMBL721541

SCHEMBL721541

SCHEMBL721541

CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 7/20 0.50
▸ AXL P30530 7/20 0.50
▸ MST1R Q04912 3/20 0.49
▸ TYRO3 Q06418 3/20 0.49
▸ MERTK Q12866 3/20 0.49
▸ PLK4 O00444 1/20 0.49
▸ ABL1 P00519 1/20 0.49
▸ NTRK1 P04629 1/20 0.49
▸ LCK P06239 1/20 0.49
▸ RET P07949 1/20 0.49
▸ KIT P10721 1/20 0.49
▸ PDGFRA P16234 1/20 0.49
▸ PRKACA P17612 1/20 0.49
▸ KDR P35968 1/20 0.49
▸ FLT3 P36888 1/20 0.49
▸ ABL2 P42684 1/20 0.49
▸ FRK P42685 1/20 0.49
▸ DDR1 Q08345 1/20 0.49
▸ PDE4D Q08499 1/20 0.49
▸ MAP4K2 Q12851 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14705756 0.90 MET (0.50) METAXLMST1RTYRO3MERTK
SCHEMBL18186587 0.89 MET (0.53) METAXLMST1RTYRO3MERTK
SCHEMBL23071634 0.88 MET (0.52) METAXLMST1RTYRO3MERTK
SCHEMBL2592272 0.88 MET (0.51) METAXLMST1RTYRO3MERTK
SCHEMBL16366161 0.88 LMNA (0.41) METAXLMST1RTYRO3MERTK
SCHEMBL15506038 0.88 GLA (0.43) METAXLMST1RTYRO3MERTK
SCHEMBL21385115 0.87 CYP1A2 (0.41) METAXLMST1RTYRO3MERTK
SCHEMBL3665276 0.87 AXL (0.49) METAXLMST1RTYRO3MERTK
SCHEMBL21383502 0.87 MET (0.43) METAXLMST1RTYRO3MERTK
SCHEMBL15946923 0.86 MET (0.48) METAXLMST1RTYRO3MERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 — — EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 — — EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 — — WO claimed
US-20260132158-A1 PHENYL OXY AMIDE KINASE INHIBITORS THE TRANSLATIONAL GENOMICS RESEARCH INST (US) 2026-05-14 — — US disclosed
US-12202835-B2 Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) 2025-01-21 — — US disclosed
WO-2024251182-A1 QUINOXALINE COMPOUND AND USE THEREOF 广州六顺生物科技有限公司 2024-12-12 — — WO disclosed
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR LG CHEM, LTD. (KR) 2024-09-05 — — US disclosed
WO-2024134514-A1 NOVEL COMPOUND AS RON INHIBITOR 주식회사 엘지화학 2024-06-27 — — WO disclosed
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 — — US disclosed
EP-3762392-B1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO LTD (KR) 2024-05-15 — — EP disclosed
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS LG CHEM, LTD. (KR) 2024-05-09 — — US disclosed
US-8558000-B2 4-pyridinone compounds and their use for cancer BRISTOL-MYERS SQUIBB COMPANY (US) 2013-10-15 — — US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 — — US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 — — EP disclosed
WO-2013078295-A2 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-05-30 — — WO disclosed
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC. (US) 2012-07-05 — — US disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 — — WO disclosed
EP-2235001-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER Bristol-Myers Squibb Company (US) 2010-10-06 — — EP disclosed
WO-2009094427-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-30 — — WO disclosed
WO-2009094427-A1 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER BRISTOL-MYERS SQUIBB COMPANY (US) 2009-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150325-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS MAP3K20, SBK3, MAPKAPK2 MET 686/4885AXL 913/4885MST1R 611/4885
US-20120172382-A1 PYRIDONE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES MKI67, TYMP, CCNA1 MET 2197/4885AXL 3090/4885MST1R 2902/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET MET 3/4885AXL 14/4885MST1R 87/4885
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB MET 1482/4885AXL 390/4885MST1R 247/4885
US-12202835-B2 Substituted aromatic ring-linked dioxinoquinazolines and dioxinoquinolines as kinase inhibitors MERTK, AXL, TYRO3 MET 12/4885AXL 2/4885MST1R 77/4885
US-20240293386-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR MAP3K20, SBK3, MAPKAPK2 MET 657/4885AXL 842/4885MST1R 544/4885
US-20260132158-A1 PHENYL OXY AMIDE KINASE INHIBITORS RAF1, CNKSR1, PHKG1 MET 186/4885AXL 377/4885MST1R 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.